Brought to you by 
Pfizer hands over EGFR inhibitor to partner OSI
Jul 2000
Executive Summary
Pfizer is relinquishing to OSI Pharmaceuticals, royalty-free, all development and marketing rights to CP-358,774 (OSI-774), an oral inhibitor of the epidermal growth factor receptor oncogene that the companies have been developing since 1986. Because Pfizer is acquiring Warner-Lambert, which is also developing an EGFR inhibitor, the FTC is requiring it to divest the product.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer hands over EGFR inhibitor to partner OSI
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice